Article
P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine.
Journal of the National Cancer Institute - 4 May 1994
Speicher L A, Barone L R, Chapman A E, Hudes G R, Laing N, Smith C D, Tew K D
Abstract excerpt
BACKGROUND: Previous preclinical studies of combinations of estramustine and vinblastine or paclitaxel (Taxol) have shown that it is possible to achieve a greater than additive cytotoxicity with these antimicrotubule drug combinations. Phase II studies in hormone-refractory prostate cancer have demonstrated clinical antitumor activity of sufficient magnitude to stimulate further laboratory and clinical studies of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
